KUALA LUMPUR, July 28 (Bernama) -- Medisca has announced the expansion of a network of strategic partnerships aimed at securing and stabilising worldwide access to high quality active pharmaceutical ingredients (APIs) for the preparation of essential medications.
In a statement, Medisca said this mission started with the exclusive partnership for Thyroid USP in 2021, and now expanded to include Progesterone USP (Special Micronized), Testosterone USP (Micronized), Diclofenac Sodium USP, and Ketamine Hydrochloride USP.
“We are steadfast in our commitment to promoting pharmaceutical compounding as a legitimate, effective, and essential solution for healthcare providers working to overcome challenges in medication accessibility and looking to provide transformative options for personalised patient care.
“To achieve this, we continue our mission to forge partnerships with leaders in API manufacturing that are unified by a common commitment to quality, consistency and value,” said Medisca Senior Vice President of Global Strategy & Innovation, Panagiota Danopoulos.
In recent years, Medisca has seen significant increases in the demand for these APIs with commercial drug shortages and the need for qualified products and transparency documented as the primary causes.
By actively engaging in strategic partnerships, Medisca reinforces its position as a true Partner In Wellness and driver in securing high-quality product supply for the pharmaceutical compounding and healthcare industries.
In order to vet the right partners, Medisca conducts thorough due diligence to ensure the highest quality measures are met at the source, whereby all partners undergo a rigorous vendor qualification programme with proof of FDA registration, quality agreements in place and testing performed to verify the quality of the product.
Leveraging these strong partnerships in API manufacturing and collaborating closely with government authorities, Medisca is able to support market access to essential APIs and address the critical needs of healthcare providers and patients globally.
-- BERNAMA
No comments:
Post a Comment